[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Endocrinology](https://durgical.com/en/endocrinology/) › [Calcium, parathyroid and bone](https://durgical.com/en/endocrinology/areas/calcium-bone/) › Treating osteoporosis: antiresorptive or anabolic, and drug holidays

# Treating osteoporosis: antiresorptive or anabolic, and drug holidays

- Follow-up and treatment

[Osteoporosis](https://durgical.com/en/conditions/osteoporosis/) medicines cut fracture risk sharply, but each one behaves differently when it is stopped. Choosing the drug means planning its exit.

Updated Nov 16, 2026

**See it in 3D:** [Femur](https://durgical.com/en/anatomy/femur/) · [L1 vertebra](https://durgical.com/en/anatomy/lumbar-vertebra/) · [L2 vertebra](https://durgical.com/en/anatomy/lumbar-vertebra-spine-and-pelvis/)

## Key points

- Oral bisphosphonate = first line; taken fasting, upright, with plain water.
- Very high risk → anabolic first, then antiresorptive.
- [Denosumab](https://durgical.com/en/pharmacology/denosumab/): never stop without a follow-on bisphosphonate (rebound vertebral fractures).
- Bisphosphonate holiday after about 5 years oral or 3 years intravenous, if risk has fallen.
- Rare harms: atypical femoral fracture, jaw [osteonecrosis](https://durgical.com/en/general-pathology/osteonecrosis/).
- [Romosozumab](https://durgical.com/en/pharmacology/romosozumab/): avoided after a recent heart attack or stroke.

On this page

- The basics Key points
- What it is
- How to think about it
- What to know
- Step by step
- Antiresorptive or anabolic
- Common traps
- Elsewhere in DurgiPedia

- Clinical In the clinic

- Treatment Next step / Initial management

- Study Test yourself

- Connections Connections

## What it is

Bone is constantly remodelled: [osteoclasts](https://durgical.com/en/physiology/bone-remodeling/) dig, osteoblasts fill. Osteoporosis drugs either slow the diggers (antiresorptives: [bisphosphonates](https://durgical.com/en/pharmacology/classes/bisphosphonates/), denosumab, [raloxifene](https://durgical.com/en/pharmacology/raloxifene/), oestrogen) or drive the fillers (anabolics: the PTH analogues [teriparatide](https://durgical.com/en/pharmacology/teriparatide/) and [abaloparatide](https://durgical.com/en/pharmacology/abaloparatide/), and romosozumab, an antibody to sclerostin that also slows resorption). All of them sit on a base of enough calcium and [vitamin D](https://durgical.com/en/biochemistry/molecules/vitamin-d/), exercise, [fall prevention](https://durgical.com/en/nursing/preventing-falls-risk-assessment-and-measures/) and not smoking. Oral bisphosphonates are first line for most patients. Very high-risk patients (a recent fracture, several vertebral fractures, a fracture on treatment, or a very low [T-score](https://durgical.com/en/endocrinology/osteoporosis-dxa-t-score-versus-z-score-and-fracture-risk/)) do better starting with an anabolic, always followed by an antiresorptive to keep the gain. The drugs differ most when they are stopped: bisphosphonates stay in bone for years, so a planned «drug holiday» is possible; denosumab and the anabolics wear off within months, so another drug must follow.

## How to think about it

Know each drug by its exit. Bisphosphonates bind into bone and leave slowly, like a long-lasting varnish: you can pause them. Denosumab is a hand holding the brake on remodelling: let go and turnover races, so the next drug must already be in place. Anabolics build new bone that is lost again unless an antiresorptive locks it in. Pick the drug and its exit together.

## What to know

- The base for everyone: enough dietary calcium and vitamin D, weight-bearing and resistance exercise, fall prevention, no smoking and little alcohol.
- Oral bisphosphonates ([alendronic acid](https://durgical.com/en/pharmacology/alendronic-acid/), [risedronic acid](https://durgical.com/en/pharmacology/risedronic-acid/), [ibandronic acid](https://durgical.com/en/pharmacology/ibandronic-acid/)) are first line; they are taken fasting with plain water, staying upright afterwards, because they are barely absorbed and irritate the oesophagus.
- Intravenous [zoledronic acid](https://durgical.com/en/pharmacology/zoledronic-acid/) suits people who cannot take or absorb tablets; the first infusion can cause a short flu-like reaction.
- Bisphosphonates are avoided when [eGFR](https://durgical.com/en/biochemistry/topics/creatinine-and-estimated-glomerular-filtration-rate/) is below about 30–35 mL/min; denosumab is not cleared by the kidney but causes more [hypocalcaemia](https://durgical.com/en/conditions/hypocalcaemia/) in advanced CKD.
- Denosumab, an antibody to RANKL, must never simply be stopped: within months bone turnover rebounds and multiple vertebral fractures can follow, so a bisphosphonate is planned to follow it.
- Anabolics: teriparatide and abaloparatide (PTH analogues) for a limited course, romosozumab for a year (avoided after a recent heart attack or stroke); each is followed by an antiresorptive.
- Raloxifene (a SERM) protects the spine but not the hip, lowers [breast cancer](https://durgical.com/en/conditions/breast-cancer/) risk and raises venous clot risk; menopausal oestrogen also protects bone in younger women treated for symptoms.
- Rare safety facts: atypical femoral fracture (thigh or groin pain, a transverse shaft fracture) rises with years of antiresorptive use; jaw osteonecrosis is rare in osteoporosis treatment and commoner in cancer care and after dental extractions.
- Drug holiday: after about 5 years of oral or 3 years of intravenous bisphosphonate, patients whose risk has fallen may pause and be reassessed; those still at high risk continue (up to about 10 or 6 years) or switch.

## Step by step

- Classify risk: high (osteoporosis or high FRAX) or very high (recent or multiple fractures, fracture on treatment, very low T-score).
- Correct vitamin D and calcium, and check [creatinine](https://durgical.com/en/biochemistry/molecules/creatinine/) and calcium, before any antiresorptive.
- Arrange dental care first if [teeth](https://durgical.com/en/embryology/teeth/) need work, especially before intravenous bisphosphonate or denosumab.
- High risk: start an oral bisphosphonate; use zoledronic acid or denosumab if tablets are not possible or the kidney rules them out.
- Very high risk: start an anabolic, then switch to an antiresorptive when the course ends.
- Review adherence and side effects; repeat DXA after 1–2 years; a new fracture or a clear loss means treatment failure.
- After 3–5 years of bisphosphonate, reassess: pause if risk has fallen, continue or switch if not.
- If denosumab is stopped, start a bisphosphonate at the time the next denosumab injection would have been due.

## Antiresorptive or anabolic

| Drug (class) | How it works | Main use | On stopping | Key safety points |
| --- | --- | --- | --- | --- |
| Oral bisphosphonates | Bind bone mineral and switch off osteoclasts | First line in most patients | Effect lingers for years; holiday possible | Oesophagitis; avoid with low eGFR; atypical femoral fracture and jaw osteonecrosis (rare) |
| Zoledronic acid (intravenous) | Same, given by infusion | Cannot take tablets; after a hip fracture | Effect lingers for years | Acute-phase reaction; hypocalcaemia; kidney function |
| Denosumab | Antibody to RANKL; stops osteoclasts forming | Kidney disease, tablet intolerance, high risk | Rebound turnover and vertebral fractures; never stop without a follow-on drug | Hypocalcaemia, especially in CKD; jaw osteonecrosis (rare) |
| Raloxifene (SERM) | Oestrogen-like action on bone | Spine protection when breast cancer risk also matters | Effect fades | Venous thrombosis; [hot flushes](https://durgical.com/en/obstetrics-gynaecology/menopause-symptoms-hormone-therapy-and-long-term-health/); no hip benefit |
| PTH analogues (teriparatide, abaloparatide) | An intermittent PTH signal builds bone | Very high risk; severe glucocorticoid osteoporosis | Gain is lost unless an antiresorptive follows | [Hypercalcaemia](https://durgical.com/en/conditions/hypercalcaemia/); avoided with open growth plates, Paget disease or previous bone radiation |
| Romosozumab | Antibody to sclerostin: builds bone and slows resorption | Very high risk | Gain is lost unless an antiresorptive follows | Avoided after a recent heart attack or stroke |

## In the clinic

- After a hip fracture, treatment is often forgotten: start it in hospital or at discharge; zoledronic acid after hip fracture also lowered mortality in a trial.
- Most «treatment failures» are tablets taken wrongly or not at all: ask how the patient takes them before switching.
- Fracture liaison services, in which a coordinator finds every fragility fracture, close the gap between fracture and treatment.

## Next step / Initial management

- Before starting: calcium, creatinine (eGFR), 25-OH vitamin D; correct low vitamin D and calcium first.
- Follow-up: DXA after 1–2 years; bone turnover markers (CTX for antiresorptives, P1NP for anabolics) can show that the drug is working and being taken.
- Thigh or groin pain on an antiresorptive: X-ray both femurs; stop the antiresorptive if an atypical fracture is found.
- Stopping denosumab: start a bisphosphonate on schedule, without a gap.
- Refer to endocrinology very high risk needing an anabolic, a fracture on treatment, CKD stage 4–5, premenopausal women and men with unexplained osteoporosis.

## Common traps

- **Every osteoporosis drug can be paused after five years**: only bisphosphonates, which stay in bone, allow a holiday; stopping denosumab triggers rebound vertebral fractures.
- **Jaw osteonecrosis makes osteoporosis treatment too dangerous**: it is rare in osteoporosis treatment, and the fractures prevented far outnumber the cases.
- **An anabolic course is complete in itself**: the new bone is lost within about a year unless an antiresorptive follows.
- **Bisphosphonates can start while vitamin D is low**: correct it first, or hypocalcaemia and a poor response follow and an [osteomalacia](https://durgical.com/en/conditions/rickets-and-osteomalacia/) stays untreated.
- **Anabolics are a last resort after bisphosphonates fail**: in very high-risk patients, starting with an anabolic prevents more fractures than starting with an antiresorptive.

## Test yourself

Think of the answer, then tap the question to see it.

## A 70-year-old woman stopped denosumab on her own after four years and now has three new vertebral fractures. What happened?

Rebound: as denosumab wears off, osteoclast activity overshoots and bone is lost fast, causing multiple vertebral fractures. Stopping must be covered by a bisphosphonate.

## A 66-year-old woman on alendronic acid for seven years has new aching in both thighs. What must you exclude, and how?

An atypical femoral fracture: X-ray both femurs (MRI if the X-ray is normal); if found, stop the bisphosphonate and refer to orthopaedics.

## Why can bisphosphonates be paused when denosumab cannot?

Bisphosphonates bind bone mineral and are released for years, so some effect remains; denosumab is an antibody cleared within months, so its effect switches off.

## A 75-year-old woman with a T-score of −3.4 and two recent vertebral fractures asks which drug comes first. What is the principle?

She is at very high risk: start an anabolic (a PTH analogue or romosozumab), then follow it with an antiresorptive to keep the gain.

[Add to my cards (4)](https://durgical.app/estudiar/?add=/en/endocrinology/treating-osteoporosis-antiresorptive-or-anabolic-and-drug-holidays/)

## Elsewhere in DurgiPedia

- [Osteoporosis](https://durgical.com/en/general-pathology/osteoporosis/)
- [Bone remodeling](https://durgical.com/en/physiology/bone-remodeling/)
- [Osteoporosis after menopause](https://durgical.com/en/obstetrics-gynaecology/osteoporosis-after-menopause/)
- [Bone turnover markers and bone matrix proteins](https://durgical.com/en/biochemistry/topics/bone-turnover-markers-and-bone-matrix-proteins/)
- [Osteonecrosis (avascular necrosis)](https://durgical.com/en/general-pathology/osteonecrosis/)

## Connections

## See it in 3D 3

The structures of Durgical's 3D anatomy where it is found.

- [Femur](https://durgical.com/en/anatomy/femur/)
- [L1 vertebra](https://durgical.com/en/anatomy/lumbar-vertebra/)
- [L2 vertebra](https://durgical.com/en/anatomy/lumbar-vertebra-spine-and-pelvis/)

## Related 4

- [Osteoporosis: DXA, T-score versus Z-score and fracture risk](https://durgical.com/en/endocrinology/osteoporosis-dxa-t-score-versus-z-score-and-fracture-risk/)
- [Bone loss from glucocorticoids](https://durgical.com/en/endocrinology/bone-loss-from-glucocorticoids/)
- [Vitamin D: whom to test and what the result means](https://durgical.com/en/endocrinology/vitamin-d-whom-to-test-and-what-the-result-means/)
- [Low calcium: PTH, magnesium and vitamin D](https://durgical.com/en/endocrinology/low-calcium-pth-magnesium-and-vitamin-d/)

## Related conditions 4

- [Osteoporosis](https://durgical.com/en/conditions/osteoporosis/)
- [Osteoporotic vertebral compression fracture](https://durgical.com/en/conditions/osteoporotic-vertebral-compression-fracture/)
- [Femoral Neck Fracture](https://durgical.com/en/conditions/femoral-neck-fracture/)
- [Hypocalcaemia](https://durgical.com/en/conditions/hypocalcaemia/)

## In Pharmacology 14

- [Bisphosphonates](https://durgical.com/en/pharmacology/classes/bisphosphonates/)
- [Alendronic acid (alendronate)](https://durgical.com/en/pharmacology/alendronic-acid/)
- [Risedronic acid (risedronate)](https://durgical.com/en/pharmacology/risedronic-acid/)
- [Ibandronic acid](https://durgical.com/en/pharmacology/ibandronic-acid/)
- [Zoledronic acid](https://durgical.com/en/pharmacology/zoledronic-acid/)
- [Denosumab](https://durgical.com/en/pharmacology/denosumab/)
- [Parathyroid hormone (PTH) analogues](https://durgical.com/en/pharmacology/classes/parathyroid-hormone-analogues/)
- [Teriparatide](https://durgical.com/en/pharmacology/teriparatide/)
- [Abaloparatide](https://durgical.com/en/pharmacology/abaloparatide/)
- [Romosozumab](https://durgical.com/en/pharmacology/romosozumab/)
- [Raloxifene](https://durgical.com/en/pharmacology/raloxifene/)
- [Estrogens](https://durgical.com/en/pharmacology/classes/estrogens/)

## See all 14

- [Colecalciferol](https://durgical.com/en/pharmacology/colecalciferol/)
- [Calcium carbonate](https://durgical.com/en/pharmacology/calcium-carbonate/)

[← All of endocrinology](https://durgical.com/en/endocrinology/)

Educational content; it does not replace a medical assessment and is not a clinical instruction. For confusion, persistent vomiting with diabetes, fainting or very low blood pressure in someone who takes or has stopped glucocorticoids, go to an emergency department at once.

Sources: [Osteoporosis in Females](https://www.ncbi.nlm.nih.gov/books/NBK559156/) (StatPearls (NCBI Bookshelf), 2025); [Bisphosphonate](https://www.ncbi.nlm.nih.gov/books/NBK470248/) (StatPearls (NCBI Bookshelf), 2023); [Denosumab](https://www.ncbi.nlm.nih.gov/books/NBK535388/) (StatPearls (NCBI Bookshelf), 2024); [Teriparatide](https://www.ncbi.nlm.nih.gov/books/NBK559248/) (StatPearls (NCBI Bookshelf), 2024); [Romosozumab](https://www.ncbi.nlm.nih.gov/books/NBK585139/) (StatPearls (NCBI Bookshelf), 2024); [Bisphosphonate-Related Jaw Osteonecrosis](https://www.ncbi.nlm.nih.gov/books/NBK534771/) (StatPearls (NCBI Bookshelf), 2023).

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/endocrinology/treating-osteoporosis-antiresorptive-or-anabolic-and-drug-holidays/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/endocrinology/treating-osteoporosis-antiresorptive-or-anabolic-and-drug-holidays/
